City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
City of Hope Investigational Drug Services (IDS), Duarte
UC San Diego Medical Center - Encinitas, Encinitas
dan 13 lainnya

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07227415

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site, San Diego
Research Site, Santa Monica

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT05536141

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NEO-811 Los Angeles Site, Duarte
NEO-811 San Diego Site, San Diego

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07300241

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Xencor Investigative Site, Duarte
Xencor Investigative Site, Sacramento

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05433142

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Chao Family Comprehensive Cancer Center, University of California Irvine, Orange

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT06580002

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

University of Southern California, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
UCLA Department of Medicine, Los Angeles

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jun 2026 · NCT06026410

A Study of VET3-TGI in Patients With Solid Tumors

USC/Norris Comprehensive Cancer Center, Los Angeles
UC Irvine Health, Orange

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Apr 2026 · NCT06444815

64Cu-GRIP B in Patients With Advanced Malignancies

University of California, San Francisco, San Francisco

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT05888532

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

City of Hope, Duarte

Menerima pesertaStudi observasionalSukarelawan sehat diterima

Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology

VA Palo Alto Healthcare System, Palo Alto

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Des 2025 · NCT07303725

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
dan 3 lainnya

Menerima pesertaStudi observasional

Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

UCSD Moores Cancer Center, La Jolla
UCLA Medical Center, Los Angeles

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT06682793

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jun 2025 · NCT03175224

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Institute of Urology, University of Southern California., Los Angeles
University of California San Diego, Moores Cancer Center, San Diego
Stanford University, Stanford

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2022 · NCT05363657

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.